JBIO earnings analysis
What we found in JBIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Jade remains a clinical-stage biotechnology company with no approved products or product revenue and reported net losses of $55.8 million for the quarter and $96.1 million for the six-month period ended June 30, 2026. Liquidity was substantial at $461.2 million of cash, cash equivalents and investments, but management states that additional capital will be required and has authorized up to $200.0 million of potential ATM equity sales. JADE101 advanced into Phase 2 in May 2026, but increasing IgAN competition, clinical execution risk, foreign manufacturing exposure and the absence of numeric financial guidance keep the outlook bearish.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $461.2M of Cash and Investments
- The company reported $107.2 million of cash and cash equivalents and $354.0 million of investments as of June 30, 2026, or $461.2 million in aggregate liquidity.
- Clinical Investment Continues
- Management reported net losses of $55.8 million for the three months ended June 30, 2026 and $96.1 million for the six months ended June 30, 2026.
- Pipeline Funding Remains the Focus
- The accumulated deficit reached $270.5 million as of June 30, 2026, reflecting the company’s ongoing pre-commercial development spending.
- Additional Capital-Raising Capacity
- The company entered into an at-the-market sales agreement on May 7, 2026 allowing potential sales of up to $200.0 million of common stock.
- JADE101 Advances to Phase 2
- The Phase 2 clinical trial of JADE101 in IgA nephropathy was initiated in May 2026, following initiation of its Phase 1 trial in August 2025.
- Controls Rated Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected or were reasonably likely to materially affect controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Future Financing and Dilution
- Liquidity remains dependent on future financing: the company states it will require substantial additional funding, while its May 7, 2026 ATM agreement permits up to $200.0 million of equity sales that could dilute stockholders. Existing cash and investments are stated to fund operations for at least twelve months, not indefinitely.
- Foreign CMO and BIOSECURE Risk
- Manufacturing and geopolitical exposure increased through reliance on foreign CROs and CMOs. The filing cites the BIOSECURE Act enacted in December 2025 and warns that designation of a supplier as a biotechnology company of concern, or U.S.-China retaliatory actions, could restrict access to suppliers and delay development.
- IgAN Competition Is Intensifying
- Competitive and regulatory pressure in IgA nephropathy is intensifying: Trutakna received FDA accelerated approval in July 2026 after a reported 42% reduction in UPCR versus placebo, while povetacicept has an FDA PDUFA target action date of November 30, 2026.
What they said about what is next.
No revenue or EPS guidance was provided in the extracted 10-Q. Management stated that cash and cash equivalents plus investments of $461.2 million as of June 30, 2026 are expected to fund operating expenses and capital expenditure requirements for at least twelve months from issuance of the financial statements; the filing does not provide a quantitative revenue or earnings outlook.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 7, 2026
- Jade Biosciences reported a significant increase in operating expenses, primarily due to ramped up clinical activities, leading to a net loss of $40.4 million for Q1 2026. Management anticipates that existing cash of…
- 10-K · March 6, 2026
- Jade Biosciences is a clinical‑stage immunology biotech focused on engineered anti‑APRIL and B‑cell programs (lead candidate JADE101) designed for less frequent subcutaneous dosing and increased potency. The company has…
- 10-Q · November 14, 2025
- Jade Biosciences reported no product revenue and a net loss of $25,175 (in thousands) for the three months ended September 30, 2025, with GAAP EPS of $(0.48). The company significantly strengthened its liquidity…
- 10-Q · April 25, 2025
- Aerovate reported a materially lower operating loss in Q1 2025 driven by cessation of R&D: total operating expenses fell to $3,387k from $24,618k a year ago, and net loss improved to $2,518k (−$0.09 per share) versus…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing JBIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever